DeepMirror
AI-powered drug design software
- 1-20 employees
- Healthcare
- B2B
- Artificial Intelligence
- Deep Tech
- Biology
- SaaS
- Data Analysis
- Covent Garden, London, UK
Jump to section
Company mission
Make AI powered drug design as simple as a spreadsheet to empower scientists across the globe.
Our take
To help elevate biology for healthcare, DeepMirror is building a molecular drug design platform that leverages the power of generative AI to streamline the discovery of medically active molecules.
DeepMirror's AI is able to suggest realistic molecules, that could be synthesised without too much difficulty, and are both safe and active for medicinal use. Through the platform, scientists can also run custom predictions based on their own compounds and data, and rank and prioritise their synthetic targets.
Ultimately, these features have the potential to fast-track research and drug discovery, supporting better healthcare outcomes. As a spin-out of the University of Cambridge, DeepMirror benefits from a respected foundation, and has launched its Early Access Programme for the platform after a successful closed beta.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Cycle Scheme
- Frequent off-sites and other social events
- Flexible working
- Great Stash
Funding (1 round)
Sep 2021
$1.9m
SEED
Total funding: $1.9m
This company has top investors
Leadership
Max Jakobs
(CEO)Royal Academy of Engineering Enterprise Fellow from 2022 to 2023. Previously a Postdoctoral Research Fellow at the University of Cambridge, and Research Student at Osaka University.
Andrea Dimitracopoulos
(Product Lead)College Research Associate at St John's College, Cambridge. Has conducted Postdoctoral Research at the University of Cambridge and the MRC Laboratory for Molecular Cell Biology (LMCB) at UCL.
Ryan Greenhalgh
(CTO)Former Software and Machine Learning Engineer at Outfield Technologies. Previously a Research Assistant at The University of Manchester, and Research Scientist at Medtrade Products Limited.